Dr Peter K Sien, MD in Kennewick, WA - Medicare Radiation Oncology

Dr Peter K Sien, MD is a medicare enrolled "Radiology - Radiation Oncology" physician in Kennewick, Washington. He went to Medical College Of Wisconsin and graduated in 1975 and has 49 years of diverse experience with area of expertise as Radiation Oncology. He is a member of the group practice Northwest Cancer Care Associates Pc and his current practice location is 7379 W Deschutes Ave Ste 100, Kennewick, Washington. You can reach out to his office (for appointments etc.) via phone at (509) 987-1800.

Dr Peter K Sien is licensed to practice in Washington (license number ME37234) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1053399568.

Contact Information

	Dr Peter K Sien, MD
	7379 W Deschutes Ave Ste 100, Kennewick, WA 99336-7900
	(509) 987-1800
	(509) 987-1808

Physician's Profile

Full Name	Dr Peter K Sien
Gender	Male
Speciality	Radiation Oncology
Experience	49 Years
Location	7379 W Deschutes Ave Ste 100, Kennewick, Washington
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Dr Peter K Sien attended and graduated from Medical College Of Wisconsin in 1975

NPI Data:

NPI Number: 1053399568
Provider Enumeration Date: 01/04/2006
Last Update Date: 08/08/2022

Medicare PECOS Information:

PECOS PAC ID: 8022911619
Enrollment ID: I20171128002516

Medical Identifiers

Medical identifiers for Dr Peter K Sien such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1053399568	NPI	-	NPPES
CA211033	Medicaid	CA
1053399568	Other	WA	REGENCE BLUE SHIELD
1053399568	Medicaid	CA
3620029	Other	CA	CIGNA
4313432	Other	FL	AETNA
P01708893	Other	FL	RR MEDICARE
500732059	Medicaid	OR
00G322670	Medicaid	CA
4313432	Other	WA	AETNA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
2085R0001X	Radiology - Radiation Oncology	G32267 (California)	Secondary
2085R0203X	Radiology - Therapeutic Radiology	G32267 (California)	Secondary
2085R0001X	Radiology - Radiation Oncology	ME37234 (Washington)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Kadlec Regional Medical Center	Richland, WA	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Northwest Cancer Care Associates Pc	5193036390	3

News Archive

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

Rigel Pharmaceuticals, Inc. today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.

CHEST updates guidelines on therapy for pulmonary arterial hypertension

The American College of Chest Physicians announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. The company is developing a technology platform to enable selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called long non-coding RNA.

States, federal officials confront health law public education challenges, exchange implementation

States are dealing with the ramifications of the health law's federally or state-run health insurance exchanges and the essential health benefits. Also, officials confront the challenge of educating the public on the health law's provisions.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Dr Peter K Sien allows following entities to bill medicare on his behalf.

Entity Name	Multicare Health System
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760

News Archive

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

CHEST updates guidelines on therapy for pulmonary arterial hypertension

The American College of Chest Physicians announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

States, federal officials confront health law public education challenges, exchange implementation

Entity Name	Northwest Cancer Care Associates Pc
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1164810545 PECOS PAC ID: 5193036390 Enrollment ID: O20150615001025

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

CHEST updates guidelines on therapy for pulmonary arterial hypertension

The American College of Chest Physicians announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

States, federal officials confront health law public education challenges, exchange implementation

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Peter K Sien is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Peter K Sien, MD 163 Valleyview Way, South San Francisco, CA 94080-5553 Ph: (510) 410-0188	Dr Peter K Sien, MD 7379 W Deschutes Ave Ste 100, Kennewick, WA 99336-7900 Ph: (509) 987-1800

News Archive

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

CHEST updates guidelines on therapy for pulmonary arterial hypertension

The American College of Chest Physicians announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

States, federal officials confront health law public education challenges, exchange implementation

Radiology Doctors in Kennewick, WA

Mrs. Sheila D Rege, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 7379 W Deschutes Ave, Ste 100, Kennewick, WA 99336 Phone: 509-987-1800 Fax: 509-987-1808
Dr. Sandip Arvind Patidar, MD Radiology Medicare: Medicare Enrolled Practice Location: 900 S Auburn Street, Kennewick, WA 99336 Phone: 509-586-5945 Fax: 509-586-5178
Dr. Brian Douglas Lawenda, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7379 W Deschutes Ave, Suite 100, Kennewick, WA 99336 Phone: 509-987-1800 Fax: 509-987-1808
Steven J Sunderland, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 7221 W Deschutes Ave, Suite A, Kennewick, WA 99336 Phone: 509-374-4030 Fax: 509-374-4030
Dr. Andrew Thomas Roehrig, MD Radiology Medicare: Medicare Enrolled Practice Location: 7350 W Deschutes Ave Ste A, Kennewick, WA 99336 Phone: 509-737-3371 Fax: 509-736-0958
Dr. Lon Sidney Welch Jr., M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 7221 W Deschutes Ave, Suite A, Kennewick, WA 99336 Phone: 509-374-4030 Fax: 509-374-8690

Dr Peter K Sien, MD - Medicare Radiation Oncology in Kennewick, WA

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

CHEST updates guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

States, federal officials confront health law public education challenges, exchange implementation

Medicare Reassignments

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

CHEST updates guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

States, federal officials confront health law public education challenges, exchange implementation

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

CHEST updates guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

States, federal officials confront health law public education challenges, exchange implementation

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Rigel Pharmaceuticals, AstraZeneca license agreement: Waiting period under Antitrust Improvements Act expires

CHEST updates guidelines on therapy for pulmonary arterial hypertension

RaNA Therapeutics completes $20.7 million round of financing

States, federal officials confront health law public education challenges, exchange implementation

Radiology Doctors in Kennewick, WA